A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
Latest Information Update: 25 Sep 2021
At a glance
- Drugs Estriol succinate (Primary)
- Indications Atrophic vaginitis
- Focus Therapeutic Use
- Acronyms BLISSAFE
- Sponsors Itf Research Pharma
Most Recent Events
- 17 May 2021 New trial record
- 24 Feb 2017 Status changed from active, no longer recruiting to completed.